Roche to up R&D spend as it realigns operations

Share this article:
Roche announced plans to increase spending on research and development and introduced a new operating model reorganizing its development and marketing efforts. Roche said its R&D spending would rise further than the $4.8 billion it spent in 2006 over the next few years but did not provide exact figures. The drugmaker also announced plans to reorganize its business operations around five disease biology units combining discovery, R&D and marketing. The cancer drugs unit will be housed in Nutley, NJ, Roche said. The virology and inflammation units will be located in Palo Alto, CA and metabolism and central nervous system will be housed at Roche facilities in Basel, Switzerland. “By combing existing expertise in disease biology areas, we will further enhance the optimal conditions for bringing future innovations to fruition faster and more efficiently – with clear benefits for patients and doctors,” CEO Franz Humer said.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.